Regen Biopharma subsidiary files provisional patent for CAR T-cell dedifferentiation method

Regen BioPharma Inc

KCL Therapeutics, a wholly owned subsidiary, filed a provisional patent application with USPTO on August 9, 2022.
Patent covers methods, means and compositions for enhancing antitumor activity of CAR T cells through dedifferentiation.
CAR T cells are modified immune T cells that attack cancer-specific antigens; developed from bone marrow stem cells.
Provisional application marks initial step in securing IP for this cancer treatment approach.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.